Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Peñalver, FJ Marquez, JA Duran, S Giraldo, P Martin, A Montalban, C Sancho, JM Ramirez, MJ Terol, MJ Capote, FJ Gutierrez, A Sanchez, B Lopez, A Salar, A Rodriguez-Caravaca, G Canales, M Caballero, MD Lopez, JLB Carbonell, F Bordas, SF Lopez, PF Persona, EP Guillermo, AL Martin, RH Mayans, JR Palomera, L Ceballos, EP Hernandez, JAQ Grau, RR de la Cruz, F Salinas, AS Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Cancer med.

10.1002/cam4.2555 2019

2019